Correction to: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer (Nature Communications, (2022), 13, 1, (5566), 10.1038/s41467-022-32995-6)

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-022-32995-6, published online 29 September 2022 The original version of this Article omitted the Competing Interests below: ‘X.J.Z. and W.H.W. are board members for EarlyDiagnostics, Inc. X.J.Z. has an executive leadership position at EarlyDiagnostics, Inc.’ and ‘X.J.Z., W.L., W.H.W., and F.A. are stockholders of EarlyDiagnostics, Inc. M.L.S., W.Z., S.L., C.-C.L., Y.Zhou, Q.L., X.N. have stock options with EarlyDiagnostics, Inc’. The statement: ‘The authors have filed a patent application on methods described in this manuscript’ has been replaced with the statement: ‘X.J.Z., M.L.S., Y.Zhou, X.N., and W.Z. are inventors on a patent application submitted by the Regents of the University of California and licensed to EarlyDiagnostics, Inc. (Patent No. US20210404007A1). P.S.L. performed summer internships in EarlyDiagnostics, Inc. in 2021 and 2022’. in the corrected article. In addition, the original Competing Interests section contained the incorrect author initials ‘S.L.’, instead of ‘W.L’. This has been corrected in both the PDF and HTML versions of the Article.